Dr. Shah on Novel Antibodies for Patients With Myeloma

Nina Shah, MD
Published: Thursday, Jan 18, 2018



Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, classifies two antibody-type treatments for patients with myeloma.

Shah distinguishes between antibody-drug conjugates and bispecific therapies. Though both therapies target specific myeloma cells—in which a toxic drug linked to a specific antibody is carried to the corresponding myeloma cell—antibodies in bispecific therapies are also coded to their T cells. This approach uses the patient’s own T cells and antibodies with the intent of killing the myeloma cell and potentially even having some T-cell membrane, which is one of the goals of that therapy.

As advances continue to be made in this landscape, clinical trials will soon determine where to sequence these drugs and whether or not they can be administered earlier.
 


Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, classifies two antibody-type treatments for patients with myeloma.

Shah distinguishes between antibody-drug conjugates and bispecific therapies. Though both therapies target specific myeloma cells—in which a toxic drug linked to a specific antibody is carried to the corresponding myeloma cell—antibodies in bispecific therapies are also coded to their T cells. This approach uses the patient’s own T cells and antibodies with the intent of killing the myeloma cell and potentially even having some T-cell membrane, which is one of the goals of that therapy.

As advances continue to be made in this landscape, clinical trials will soon determine where to sequence these drugs and whether or not they can be administered earlier.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x